Further characterization of the GlyT-1 inhibitor Org25935 : anti-alcohol, neurobehavioral, and gene expression effects

Show full item record



Permalink

http://hdl.handle.net/10138/195928

Citation

Lido , H H , Jonsson , S , Hyytiä , P , Ericson , M & Soderpalm , B 2017 , ' Further characterization of the GlyT-1 inhibitor Org25935 : anti-alcohol, neurobehavioral, and gene expression effects ' , Journal of Neural Transmission , vol. 124 , no. 5 , pp. 607-619 . https://doi.org/10.1007/s00702-017-1685-z

Title: Further characterization of the GlyT-1 inhibitor Org25935 : anti-alcohol, neurobehavioral, and gene expression effects
Author: Lido, Helga Hoifodt; Jonsson, Susanne; Hyytiä, Petri; Ericson, Mia; Soderpalm, Bo
Contributor: University of Helsinki, Medicum
Date: 2017-05
Language: eng
Number of pages: 13
Belongs to series: Journal of Neural Transmission
ISSN: 0300-9564
URI: http://hdl.handle.net/10138/195928
Abstract: The glycine transporter-1 inhibitor Org25935 is a promising candidate in a treatment concept for alcohol use disorder targeting the glycine system. Org25935 inhibits ethanol-induced dopamine elevation in brain reward regions and reduces ethanol intake in Wistar rats. This study aimed to further characterise the compound and used ethanol consumption, behavioral measures, and gene expression as parameters to investigate the effects in Wistar rats and, as pharmacogenetic comparison, Alko-Alcohol (AA) rats. Animals were provided limited access to ethanol in a two-bottle free-choice paradigm with daily drug administration. Acute effects of Org25935 were estimated using locomotor activity and neurobehavioral status. Effects on gene expression in Wistar rats were measured with qPCR. The higher but not the lower dose of Org25935 reduced alcohol intake in Wistar rats. Unexpectedly, Org25935 reduced both ethanol and water intake and induced strong CNS-depressive effects in AA-rats (withdrawn from further studies). Neurobehavioral effects by Org25935 differed between the strains (AA-rats towards sedation). Org25935 did not affect gene expression at the mRNA level in the glycine system of Wistar rats. The data indicate a small therapeutic range for the anti-alcohol properties of Org25935, a finding that may guide further evaluations of the clinical utility of GlyT-1 inhibitors. The results point to the importance of pharmacogenetic considerations when developing drugs for alcohol-related medical concerns. Despite the lack of successful clinical outcomes, to date, the heterogeneity of drug action of Org25935 and similar agents and the unmet medical need justify further studies of glycinergic compounds in alcohol use disorder.
Subject: Alcohol use disorder
Glycine
Glycine transporter-1 inhibitors
Ethanol intake
Wistar-rats
AA-rats
CENTRAL-NERVOUS-SYSTEM
RAT NUCLEUS-ACCUMBENS
ALCOHOL-PREFERRING AA
GLYCINE TRANSPORTER
DOPAMINE RELEASE
ETHANOL INTAKE
ORG 25935
RECEPTORS
DEPENDENCE
DRINKING
3112 Neurosciences
3124 Neurology and psychiatry
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
10.1007_s00702_017_1685_z.pdf 686.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record